Time：2026-06-30
[Chengdu, June 26, 2026] Medtide Inc. (the "Company"; StockCode: 03880.HK) was officially included in the authoritative ranking Top 20Pharmaceutical CDMO Enterprises 2026 at the 2026 PDI Pharmaceutical R&D& Innovation Conference and the Launch Ceremony of Top 100 Drug R&DEnterprises List. Backed by its outstanding delivery capacity, global footprintand steady revenue growth in the peptide CDMO sector, this recognition marksanother milestone affirming the Company’s leading industry standing after overtwo decades of dedicated engagement in peptide CRDMO (Contract Research,Development and Manufacturing).
Since the launch of the 14th Five-Year Plan, China’s pharmaceuticalindustry has fully entered a new era of high-quality development led byinnovation. The number of domestic innovative drugs approved and thetransaction volume of out-licensing deals have repeatedly hit record highs,with Chinese enterprises ranking among global front-runners in cutting-edgetracks such as ADCs and cell & gene therapy. The industry is now embracinga golden age driven by dual engines of innovation and capital. Fruitfuloriginal innovation injects robust momentum into the market, while rationalcapital precisely fuels clinical value delivery. China’s pharmaceutical sectoris accelerating the formation of an efficient positive loop integrating"research – industrialization – capital", steadily advancing toward aglobal powerhouse in pharmaceuticals and delivering irreplaceable Chineseexpertise to the world.
Jointly released by the Organizing Committee of the PDI Conference and Yaozhi.com, the Top 20Pharmaceutical CDMO Enterprises 2026 ranking is built on objective big data anda multi-dimensional quantitative evaluation framework. It assesses domesticCDMO players across ten core metrics including annual revenue, profit growth,R&D investment, workforce scale, brand influence and leadership in niche segments.Medtide Inc. stands alongside industry leaders including WuXi Biologics,Asymchem, Boruida Pharmaceutical and Jiuzhou Pharmaceutical within the nationaltop 20, demonstrating its differentiated competitive edge and market leadershipin custom manufacturing for peptides and oligonucleotides (TIDES).
Being honored as one of the Top 20 Pharmaceutical CDMO Enterprises 2026serves not only as authoritative validation of Medtide Inc.’s two decades oftechnical accumulation and service capabilities in the peptide industry, butalso as a powerful impetus for the Company’s long-term development strategy.Faced with the historic opportunity brought by the global boom in peptide andoligonucleotide (TIDES) therapeutics, Medtide Inc. will take this accolade as anew starting point. Upholding the philosophy of "Innovation-Driven,Quality-First", the Company will further expand its dual China-US cGMPproduction capacity network, empowering global biotech innovators withfull-lifecycle support spanning early-stage research through commercial-scalemanufacturing. We strive to become the most trusted TIDES CRDMO partner in theglobal life sciences sector, and together with peers across China’spharmaceutical industry, leave an increasingly prominent Chinese footprint onthe global pharmaceutical innovation landscape.
About Medtide Inc.
Medtide Inc. (03880.HK) is a peptide-focused Contract Research, Development and ManufacturingOrganization (CRDMO), providing full-cycle services ranging from earlydiscovery, preclinical and clinical development to commercial manufacturing.Headquartered in Hangzhou, China, the company has commercial manufacturingbases and offices in both China and the United States. With 25 years of deepcultivation in the peptide field, Medtide Inc. is a CRDMO with global operationand integrated service capabilities.
We offer CRDMO services covering the entire life cycle of pharmaceuticalR&D, including the discovery and synthesis of New Chemical Entities (NCEs),as well as the development and commercial manufacturing of Chemistry,Manufacturing and Controls (CMC). Since its establishment, Medtide Inc. hasprovided peptide drug synthesis, development, manufacturing and CMC applicationsupport services complying with the regulatory requirements of major globalmarkets for more than 1,000 customers worldwide, with projects covering over 50countries and regions, including major markets such as China, the UnitedStates, Japan, Europe, South Korea and Australia.
As a reliable and sustainable enterprise, Medtide Inc. has establishedlong-term partnerships with many customers. Through close cooperation, thecompany helps customers bring pharmaceuticals that have a profound impact onhuman health to the market. Centering on patients, we are committed toimproving patients’ quality of life and advancing the development of the globalhuman health cause.
